Corcept's Phase 3 GRADIENT trial for relacorilant has missed its primary endpoint – the improvement in SBP for Cushing's ...

Sparrow Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology and immunology, today announced that the Phase 2 ...

Corcept Therapeutics Inc. (CORT), which posted strong financial results for the third quarter yesterday, is anticipating a ...

Salivary cortisol measurements are particularly useful to investigate cyclical Cushing's syndrome. At least partial autonomy of cortisol production (either direct from the adrenal cortex or ...

In addition, Sparrow announced that clofutriben has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) for the treatment of endogenous Cushing’s syndrome.

Online influencers claim high stress hormones cause puffy cheeks – but experts say it’s not as common as people think ...

More recently, a prospective, multicenter pilot study evaluated the effectiveness of retinoic acid in the treatment of Cushing's syndrome. Seven patients with Cushing's disease were initiated on ...

Corcept Therapeutics announced Wednesday that its experimental treatment for Cushing’s syndrome missed the primary endpoint ...

CORT beats on both earnings and sales in the third quarter of 2024. The company increases the revenue guidance for 2024. Stock falls in after-hours trading.

The firm's decision reflects a positive outlook on the company's Cushing's syndrome treatment franchise, including its flagship product, Korlym. The analyst at H.C. Wainwright cited the sustained ...

A 51-year-old man from Binh Dinh Province died after contracting the A/H1N1 swine flu virus, experiencing complications including septic shock and Cushing's syndrome.

Too much cortisol or stress hormone can lead to one of the main symptoms of Cushing syndrome: a fatty hump between the ...